Diane Reidy-Lagunes, MD, medical oncologist, associate deputy physician in chief, Regional Care Network, physician ambassador, Patient Family Advisory Council for Quality, president, MSK Medical Staff, Memorial Sloan Kettering Cancer Center, discusses the results of the phase 3 SPINET trial (NCT02683941) by tumor subtype in bronchopulmonary neuroendocrine tumors (BP-NETs).

The SPINET trial randomized patients with BP-NETs to lanreotide autogel/depot (LAN) plus best supportive care vs placebo plus best supportive care. Enrollment to the trial was stopped early because of slow accrual and because somatostatin analogs (SSAs) were added as a first-line recommendation for patients with BP-NETs in United States and European guidelines. 

During the 2021 NANETS Symposium, findings from the study were presented and confirmed the feasibility of SSAs in patients with BP-NETs, particularly in those with typical carcinoid disease, Reidy-Lagunes says.

In patients with typical carcinoid BP-NETs, the median progression-free survival (PFS) was 21.9 months with LAN vs 13.9 months with placebo. In patients with atypical carcinoid BP-NETs, the median PFS was 13.8 months vs 11 months, respectively, Reidy-Lagunes concludes.

Videos

Diane Reidy-Lagunes, MD, discusses the results of the phase 3 SPINET trial by tumor subtype in bronchopulmonary neuroendocrine tumors.

Diane L. Reidy-Lagunes, MD

Articles

Dr. Reidy-Lagunes on the Results of the SPINET Study by Tumor Subtype in BP-NETs